Cleerly

Cleerly is an FDA-cleared AI-powered cardiac imaging platform that analyzes coronary CT angiography (CCTA) scans to quantify atherosclerotic plaque burden, characterize plaque composition, and assess stenosis—providing cardiologists with a comprehensive, non-invasive assessment of coronary artery disease far beyond traditional calcium scoring. The platform's AI algorithms have been validated in multiple peer-reviewed studies demonstrating superior risk stratification compared to conventional methods, enabling earlier detection and precision management of heart disease. Backed by over $300M in funding and deployed across major cardiology practices and health systems, Cleerly is pioneering a shift toward plaque-based cardiac risk assessment in preventive cardiology.